Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV

Ashare, Rebecca L.; Thompson, Morgan; Serrano, Katrina J.; Leone, Frank T.; Metzger, David S.; Frank, Ian; Gross, Robert; Hole, Anita; Mounzer, Karam; Collman, Ronald G.; Wileyto, E. Paul; Schnoll, Robert A.

doi:10.1016/j.drugalcdep.2019.03.011

Cited by 36 publications

(28 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the substantial burden of smoking among PWH and the need for more effective treatments (Mdodo et al, 2015), the current study sought to compare patterns of quitting behavior among smokers with and without HIV who were treated with varenicline and behavioral counseling. Although our clinical trial of varenicline for HIVϩ smokers was consistent with the one other RCT that we know of in demonstrating that varenicline outperformed placebo (Ashare, Thompson, Serrano, et al, 2019;Mercié et al, 2018), the quit rates at Week 12 were still relatively low, compared to the general population. Thus, a better understanding of the dynamic processes that occur during a quit attempt could inform the development of population-specific interventions to optimize treatment (E. P. Wileyto et al, 2005).…”

Section: Discussionsupporting

confidence: 77%

“…With respect to pharmacological treatments for smoking cessation, nicotine patches combined with behavioral counseling among PWH have reported moderate effect sizes (Gritz et al, 2013; Manuel, Lum, Hengl, & Sorensen, 2013; Moadel et al, 2012), but only two studies compared the nicotine patch to no medication (Cropsey et al, 2013; Wewers, Neidig, & Kihm, 2000). Two randomized placebo-controlled trials of varenicline found that, compared to placebo, varenicline significantly increased end-of-treatment (EOT) quit rates, with cessation among varenicline-treated participants of 28–29% (Ashare, Thompson, Serrano, et al, 2019; Mercié et al, 2018). Although the data suggest that existing treatments are better than placebo/no treatment for HIV+ smokers, a better understanding of how a quit attempt typically progresses among these smokers can guide strategies to optimize treatments.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV.

Ashare¹,

Wileyto

Logue-Chamberlain³

et al. 2021

Psychology of Addictive Behaviors

Self Cite

View full text Add to dashboard Cite

Addressing tobacco use among HIVϩ smokers is a priority. Lack of knowledge about how HIVϩ smokers respond to tobacco use treatments limits our ability to effectively treat this population of smokers. Using data from 2 clinical trials that provided 12 weeks of varenicline and behavioral counseling, 1 with smokers with HIV (n ϭ 89) and 1 with smokers without HIV (n ϭ 179), we used mixed logistic regression modeling to compare point-prevalence abstinence rates and adherence to the initial target quit date (TQD) and Cox regression for repeated outcomes to evaluate lapse and recovery dynamics between the groups. Sixty percent of HIVϪ smokers refrained from smoking at the TQD while only 33% of HIVϩ smokers did (odds ratio [OR] ϭ 0.32, 95% CI [0.18, 0.56], p Ͻ .001). The point-prevalence abstinence rates at Week 12 were 31% (HIVϪ) and 28% (HIVϩ; OR ϭ 0.7, 95% CI [0.42, 1.16], p ϭ .16) and the point prevalence abstinence rates at Week 24 were 22% (HIVϪ) and 15% (HIVϩ; OR ϭ 0.87, 95% CI [0.49, 1.57], p ϭ .65). Although there was no interaction between HIV status and lapse risk, 2 (3) Ͻ 1, there was a significant interaction for the recovery model, ( 2 (3) ϭ 20.4, p Ͻ 0.001): as the number of events increased, the time to the next recovery became longer among smokers with HIV, compared to smokers without HIV. Although HIVϩ smokers were treated effectively with

show abstract

Section: Discussionsupporting

confidence: 77%

mentioning

confidence: 99%

Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV.

Ashare¹,

Wileyto

Logue-Chamberlain³

et al. 2021

Psychology of Addictive Behaviors

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our results highlight the need for robust strategies to help worldwide populations of PLH quit smoking. Whilst buproprion interacts with commonly prescribed anti-retroviral drugs, two randomised control trials have shown varencicline to be superior to placebo at achieving sustained smoking cessation among PLH, with no concerns regarding safety or drug interaction [22,96] . A 2016 Cochrane review examined smoking cessation strategies in PLH, encompassing psychotherapy and pharmacotherapy in combination or isolation.…”

Section: Discussionmentioning

confidence: 99%

Worldwide relative smoking prevalence among people living with and without HIV

Johnston

Wright

Orr

et al. 2021

Aids

View full text Add to dashboard Cite

show abstract

“…Time point prevalence was also reported as a measure for smoking abstinence rate. A recent placebo-controlled randomized clinical trial tested the efficacy and safety of varenicline in smokers with HIV 27 . Point prevalence abstinence at weeks 12 and 24 was used as a primary outcome.…”

Section: Discussionmentioning

confidence: 99%

Topiramate for smoking cessation: Systematic review and meta-analysis

Lotfy

Elsawah

Hassan

2020

Tob. Prev. Cessation

View full text Add to dashboard Cite

INTRODUCTION Topiramate is an antiepileptic drug that has been used for many labeled and off-labeled indications. It may be useful in reducing withdrawal symptoms of various addictive agents such as alcohol, cocaine, cannabis and smoking. To date, some studies have examined the effectiveness of topiramate for smoking cessation. The present review aims to synthesize the results from those studies and determine topiramate effectiveness in smoking cessation. METHODS A comprehensive search was conducted in the databases: PubMed/ Medline, Cochrane, Egyptian Knowledge Bank, and Google Scholar. All clinical trials that examined the effect of topiramate, compared with the placebo, on smoking cessation rate were included. Statistical analysis using fixed effect models, heterogeneity and sensitivity analysis were conducted using RevMan 5.3. RESULTS Five trials met the inclusion criteria and were included in the metaanalysis. Topiramate non-significantly increased prolonged smoking abstinence rate (OR=1.19, 95% CI: 0.57-2.5) compared with the placebo. On the other hand, topiramate significantly increased the abstinence rate at weeks 4

show abstract

Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV

Cited by 36 publications

References 54 publications

Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV.

Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV.

Worldwide relative smoking prevalence among people living with and without HIV

Topiramate for smoking cessation: Systematic review and meta-analysis

Contact Info

Product

Resources

About